Forward Pharma A/S (NASDAQ:FWP) Research Coverage Started at started coverage on shares of Forward Pharma A/S (NASDAQ:FWPGet Rating) in a note issued to investors on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.

Shares of Forward Pharma A/S stock opened at $5.55 on Friday. The stock’s fifty day moving average is $5.69 and its 200 day moving average is $5.83. Forward Pharma A/S has a one year low of $4.86 and a one year high of $20.31.

Large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. purchased a new position in shares of Forward Pharma A/S during the 3rd quarter worth approximately $105,000. Citadel Advisors LLC purchased a new stake in shares of Forward Pharma A/S in the third quarter valued at about $141,000. Renaissance Technologies LLC acquired a new position in Forward Pharma A/S during the third quarter worth about $597,000. Finally, Morgan Stanley raised its position in shares of Forward Pharma A/S by 6.8% in the third quarter. Morgan Stanley now owns 194,129 shares of the biotechnology company’s stock valued at $1,320,000 after buying an additional 12,330 shares during the last quarter. 10.41% of the stock is currently owned by institutional investors.

About Forward Pharma A/S (Get Rating)

Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.

Featured Stories

Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with's FREE daily email newsletter.